Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noboru Yamamoto

Showing results (31-40 of 437) with videos related to

Pageof 44
Sort By:
Cancer Treatment Reviews|May 18, 2004
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trialsIkuo Sekine, Noboru Yamamoto, Hideo Kunitoh, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|August 8, 2012
[Ventricular septation using two-patch technique for total inlet-trabecular septal defect]Tai Fuchigami, Yusuke Iwata, Kazuaki Ishihara, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2006
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancerIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2007
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsNoboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, et al.
International Journal of Clinical Oncology|November 7, 2022
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label studyShunsuke Kondo, Satoru Iwasa, Takafumi Koyama, et al.
Cancer|July 28, 2005
A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapyKan Yonemori, Noriyuki Katsumata, Noboru Yamamoto, et al.
Cancer Science|June 29, 2007
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicityIkuo Sekine, Kazuhiko Yamada, Hiroshi Nokihara, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 7, 2008
Long-term outcomes and social independence level after arterial switch operationAkira Yamazaki, Noboru Yamamoto, Takahiko Sakamoto, et al.
Clinical Lung Cancer|December 17, 2022
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 AberrationsJohn Heymach, Frans Opdam, Minal Barve, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsHaruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, et al.
Pageof 44

Showing results (31-40 of 437) with videos related to

Sort By:
Pageof 44
Cancer Treatment Reviews|May 18, 2004
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trialsIkuo Sekine, Noboru Yamamoto, Hideo Kunitoh, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|August 8, 2012
[Ventricular septation using two-patch technique for total inlet-trabecular septal defect]Tai Fuchigami, Yusuke Iwata, Kazuaki Ishihara, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2006
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancerIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2007
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsNoboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, et al.
International Journal of Clinical Oncology|November 7, 2022
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label studyShunsuke Kondo, Satoru Iwasa, Takafumi Koyama, et al.
Cancer|July 28, 2005
A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapyKan Yonemori, Noriyuki Katsumata, Noboru Yamamoto, et al.
Cancer Science|June 29, 2007
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicityIkuo Sekine, Kazuhiko Yamada, Hiroshi Nokihara, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 7, 2008
Long-term outcomes and social independence level after arterial switch operationAkira Yamazaki, Noboru Yamamoto, Takahiko Sakamoto, et al.
Clinical Lung Cancer|December 17, 2022
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 AberrationsJohn Heymach, Frans Opdam, Minal Barve, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsHaruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, et al.
Pageof 44